AssetMark Inc’s Dyne Therapeutics DYN Stock Holding History

AssetMark Inc’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$636K	Sell	28,621 -2,441	-8%	-$45.4K	﹤0.01%	1178
2026 Q1	$563K	Buy	+31,062	New	+$536K	﹤0.01%	1143

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AssetMark Inc's DYN Position: Q2 2026 in Review

AssetMark Inc reduced its Dyne Therapeutics (DYN) stake by 7.9% in Q2 2026, selling an estimated $45.4K and leaving 28,621 shares worth $636K. The position accounts for ﹤0.01% of the portfolio, ranked #1178.

AssetMark Inc first reported a position in DYN in Q1 2026 and has held it in 2 quarters since. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

AssetMark Inc held 28,621 shares of Dyne Therapeutics worth $636K as of Q2 2026.
AssetMark Inc sold 2,441 Dyne Therapeutics shares in Q2 2026, an estimated $45.4K.
Dyne Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #1178 holding.
AssetMark Inc first reported a position in Dyne Therapeutics in Q1 2026 and has held it in 2 quarters since.
245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.